S-P's Suboxone approved in Scotland
US drug major Schering-Plough's UK subsidiary says that Suboxone (buprenorphine HCl plus naloxone HCl) sublingual tablets for maintenance treatment of opioid dependence has been recommended by the Scottish Medicines Consortium for use under the National Health Service.
The SMC's view, which specifies that the product is used as part of a framework of medical, social and psychological therapy, is primarily based on data from a one-year clinical trial in opioid-dependent patients, which showed that individuals receiving the drug produced a significantly-higher proportion of opioid-free urine samples than those given placebo.
S-P noted that an estimated 51,000 people in Scotland experience problem drug use of opiods or benzodiazepines, of which over 18,000 are thought to inject their drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze